Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Flare Risk Increases When Medication Is Stopped Prior to Arthroplasty

Vanessa Caceres  |  June 21, 2018

After total hip or knee arthroplasty, flares are common in patients with rheumatoid arthritis (RA), according to a recently published study.1 Higher disease activity at baseline appears to be linked to flares, but use of such medications as biologics and methotrexate did not independently predict flaring. “Contrary to the notion that patients with established RA…

Filed under:Rheumatoid Arthritis Tagged with:arthroplastyflarehip replacementknee replacement

Figure 1. A nasal biopsy shows intimal infiltration of the small blood vessels (black arrow).

Case Illustrates the Difficulty Diagnosing Granulomatosis with Polyangiitis

Diana Girnita, MD, PhD, & Vishnuteja Devalla, MD  |  June 21, 2018

Granulomatosis with polyangiitis (GPA) was first described in the British Medical Journal in 1897 by Scottish otolaryngologist Peter McBride.1 GPA is a relatively rare, systemic necrotizing vasculitis that can make diagnosis challenging. The incidence has been estimated anywhere between two and 12 cases per million.2 GPA mainly affects adults between the ages of 45 and…

Filed under:Vasculitis Tagged with:ANCAanti-neutrophil cytoplasmic antibodies (ANCA)BiomarkersbiopsyGPAgranulomatosis with polyangiitis

Researchers Seek to Predict & Prevent Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc, & Kevin D. Deane, MD, PhD  |  June 21, 2018

Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…

Filed under:Rheumatoid Arthritis Tagged with:lifestyleMetricsrisk assessmentRisk Factors

Dr. Ellen M. Gravallese In the Spotlight

Gretchen Henkel  |  June 21, 2018

Robert Finberg, MD, chair of medicine at the University of Massachusetts (UMass) in Worcester, describes Ellen M. Gravallese, MD, as one of a dying breed: a quadruple-threat physician who excels in basic science research, clinical care, teaching and administration. Dr. Gravallese holds the Myles J. McDonough Chair in Rheuma­tology, is professor of medicine and serves…

Filed under:From the CollegeProfiles Tagged with:Dr. Ellen M. Gravallese

Lightspring / Shutterstock.com

When & How to Talk to Your Patients About Their Gender & Sex

Susan Bernstein  |  June 21, 2018

How do you ask a new patient about sex and gender—or know which pronoun to use? Keep the conversation straightforward and respectful to put everyone at ease, says Morgan Orndorff, a transgender man who works as an administrator at a major academic medical center. “Everyone is a little different in terms of their sensitivity level”…

Filed under:Patient PerspectiveProfessional Topics Tagged with:GenderLGBTQsex

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 18, 2018

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:Certolizumab PegolFDAFDA approvalplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)

Fed Up with Rising Costs, Big U.S. Firms Dig Into Healthcare

Caroline Humer  |  June 12, 2018

SAN JOSE, Calif., (Reuters)—At its Silicon Valley headquarters, network gear maker Cisco Systems Inc. is going to unusual lengths to take control of the relentless increase in its U.S. healthcare costs. The company is among a handful of large American employers who are getting more deeply involved in managing their workers’ health instead of looking…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Cisco Systems Inc.Healthcarehealthcare cost

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  June 11, 2018

Denosumab is now approved to treat adults with glucocorticoid-induced osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabFDAGlucocorticoid-Induced OsteoporosisOsteoporosisosteoporosis treatmentsU.S. Food and Drug Administration (FDA)

ACR’s Affiliate Society Council Reports Solid Gains in Advocacy Efforts

Gretchen Henkel  |  June 7, 2018

It’s May, and soon, most state legislatures will be adjourning for the remainder of the year. Joseph Cantrell, JD, senior manager of state affairs for the ACR, who tracks the progress of state and federal patient care legislation, reports that several states saw solid gains during 2018 state sessions, which typically run from January to…

Filed under:Legislation & Advocacy Tagged with:Affiliate Society Council (ASC)Joseph Cantrellpharmacy benefit managers (PBMs)state legislation

FDA Updates Ixekizumab Label to Include Genital Area Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 6, 2018

Ixekizumab is the first agent approved by the FDA for treating plaque psoriasis to include labeling for psoriasis in the genital area…

Filed under:ConditionsDrug Updates Tagged with:FDAgenital psoriasisixekizumabPsoriasisU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 151
  • 152
  • 153
  • 154
  • 155
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences